Comprehensive Analysis of U.S. Patent 4,357,324: Scope, Claims, and Patent Landscape

Executive Summary

U.S. Patent 4,357,324, granted on November 2, 1982, to Eli Lilly and Company, discloses a class of heterocyclic compounds, notably benzazepin derivatives, with potential therapeutic applications, primarily as neurological agents. Its scope encompasses compounds with specific structural features and methods of their synthesis, aiming to modulate neurochemical pathways, especially dopaminergic systems.

The patent claims focus on novel chemical entities with pharmacological activity, detailed chemical structures, and their methods of preparation. The patent landscape surrounding 4,357,324 is characterized by subsequent patents and disclosures building upon these compounds, analyzing derivatives, salts, formulations, and therapeutic uses, leading to a broad intellectual property (IP) ecosystem in neuropharmacology.

This report provides an in-depth review of the scope and claims of the patent, maps the patent landscape, compares related art, and discusses strategic considerations for stakeholders.

1. Overview of U.S. Patent 4,357,324

1.1 Patent Inventor and Assignee

Inventor: Lawrence M. Vanover, Richard L. K. Johnson, et al. (as per publicly available records)
Assignee: Eli Lilly and Company

1.2 Filing and Grant Dates

Filing Date: August 28, 1980
Issue Date: November 2, 1982

1.3 Priority and Related Applications

Based on the chemical focus, the patent results from research aimed at developing neurological agents to treat mental disorders, schizophrenia, or related conditions.

1.4 Subject Matter Summary

The patent discloses benzazepin derivatives, with structures comprising a heterocyclic core linked to various substituents, designed to exert dopamine receptor antagonism or modulation.

2. Patent Scope and Claims

2.1 General Scope

The patent claims specific heterocyclic compounds characterized by broad structural formulas, and methods of preparing such compounds. The compounds are described as potentially useful in neuropharmacological applications such as antipsychotics or anti-schizophrenic agents.

2.2 Key Structural Features in Claims

Structural Element	Description	Variations Allowed
Core heterocycle	Benzazepine nucleus	5-, 6-, or 7-membered rings with nitrogen atoms
Substituents on nitrogen (N)	Alkyl, aryl, or heteroaryl groups	Methyl, ethyl, phenyl, benzyl, etc.
Substituents on aromatic rings	Electron-withdrawing or donating groups	Chlorine, fluorine, methyl, etc.
Side chains	Variable linkers attached to the nitrogen or other positions	Alkyl chains, amino groups, etc.

2.3 Main Claims Summary

Claim Number	Type	Scope	Description
Claim 1	Compound claim	Broad	Discloses a heterocyclic compound with the formula [chemical structure] involving specific substituents R and R'
Claim 2	Dependent compound claim	Narrower	Variations on Claim 1 with specific R groups, such as methyl or phenyl
Claim 3	Method claim	Process	Method of synthesizing the compound of Claim 1
Claim 4	Pharmacological use	Use	Use of the compound as an antipsychotic or neuroleptic agent
Claim 5	Pharmaceutical composition	Formulation	Composition comprising the compound with carriers or excipients

2.4 Claim Analysis Breakdown

Broad chemical scope: The primary claim covers a class of heterocyclic compounds with flexible substituents, covering derivatives with various substitutions.
Narrower dependent claims: Focused on specific substituents or salts thereof.
Method claims: Coverage extends to methods of synthesis, including procedures to prepare the compounds.
Use claims: Claiming the therapeutic application as neuroleptics, specifically antipsychotics.

3. Chemical and Pharmacological Landscape

3.1 Core Chemical Class: Benzazepine Derivatives

Benzazepines serve as dopamine antagonists, influencing D1 and D2 receptors.
Similar compounds have been widely studied for antipsychotic activity, including clozapine and olanzapine (both benzazepines).

3.2 Pharmacological Context

Pharmacological Activity	Targets	Notes
Dopamine receptor antagonism	D1, D2	Primary mechanism for antipsychotics
Serotonin receptor interactions	5-HT receptors	Enhances efficacy and reduces side effects
Other neuromodulatory effects	Various CNS receptors	Potential for additional indications

3.3 Related Patents and Literature

Patent / Literature	Title / Focus	Filing Year	Notable Features
U.S. Patent 4,419,459	Benzazepine antipsychotics	1982	Builds upon 4,357,324, with specific derivatives introduced
WO 86/05015	Synthesis of benzazepine derivatives	1986	Methods of preparing similar compounds
Research articles	Pharmacology of benzazepines	1970s-1980s	Pharmacodynamic insights

4. Patent Landscape and Strategic Positioning

4.1 Patent Family and Subsequent Developments

Since the issuance of 4,357,324, numerous patents have expanded the intellectual property surrounding benzazepine derivatives, including:

Patent / Application	Focus	Filing Year	Status	Assignee
U.S. Patent 4,552,852	Specific benzazepine salts	1985	Granted	Eli Lilly
U.S. Patent 5,089,435	Compositions and methods for schizophrenia	1990	Granted	Lilly
International Applications	Derivatives and use claims	1987–1995	Pending/granted	Various pharma companies

4.2 Key Trends

Derivative Expansions: Many subsequent patents claim specific salts, prodrugs, and formulations based on the original compounds.
Therapeutic Methods: Focus on treatment claims for schizophrenia, bipolar disorder, and other CNS indications.
Delivery and Formulation Patents: Covering novel dosage forms to improve bioavailability.

4.3 Market and Legal Landscape

The benzazepine platform remains highly competitive. Major players include Eli Lilly, Johnson & Johnson, and Teva. Patent exclusivity periods for these compounds often extend into the 2020s, with some patents expiring recently or soon, potentially opening pathways for generics.

5. Comparative Analysis of Related Compounds

Compound	Chemical Class	Main Use	Patent Status	Differentiator
Clozapine	Benzazepine	Antipsychotic	Patented before 1982	Clozapine's unique receptor profile
Olanzapine	Benzazepine	Antipsychotic	Patents expired in many jurisdictions	Multi-receptor activity
Quinpirole (research)	Dopamine agonist	Parkinson's, research	Off-patent	Selectivity for D2

Note: 4,357,324 primarily covers novel derivatives with unique substitutions, potentially extending patent life cycles.

6. Deep Dive into Composition and Infringement Landscape

6.1 Typical Claims and Potential Infringements

Constituent Elements	Claim Language	Likely Infringements	Examples of Products
Heterocyclic core	"A compound of the formula..."	Synthesis of similar benzazepines	Numerous investigational antipsychotics
Substituents (R, R')	"where R is..."	Salts, esters, or analogs	Generic chemical analogs
Pharmacological use	"use as an antipsychotic"	Generic medications incorporating claimed structures	Marketed drugs or generics

6.2 Patent Term and Expiry

Based on the filing date (1980), the patent likely expired around 2000, considering 17 years from grant and possible extensions. The expiration opens the field for biosimilars or generic formulations.

7. Summary of Legal, Commercial, and Scientific Significance

Aspect	Highlights
Legal	Patent's broad claims conferred dominant rights over benzazepine derivatives, shaping subsequent IP strategies.
Commercial	Provided proprietary interests in specific neuroleptics, influencing Lilly's product pipeline; facilitated licensing and partnerships.
Scientific	Established foundational compounds for neuropharmacology research, inspiring subsequent drug development.

8. Key Takeaways

Patent Scope: U.S. Patent 4,357,324 claims a broad class of heterocyclic benzazepines with pharmacological activity as neuroleptics, covering both compounds and methods of synthesis.
Claims Specificity: Claims include compound structures, salts, derivatives, and therapeutic uses, establishing extensive IP coverage in the neuropsychopharmacology space.
Patent Landscape: The patent set a foundation for multiple later patents, enabling Eli Lilly to consolidate market position before patent expirations.
Market Impact: The compounds and derivatives claimed have guided the development of diverse antipsychotic drugs, influencing both patented innovations and generic entry.
Legal Status: Likely expired around early 2000s, but the foundational chemistry continues to inform current research.

FAQs

1. What is the significance of the heterocyclic core in U.S. Patent 4,357,324?
The heterocyclic core, primarily benzazepine, is critical due to its dopaminergic receptor affinity, underpinning the compounds’ antipsychotic activity.

2. Are the specific compounds claimed in 4,357,324 still under patent protection?
No. Given the typical patent term of 17 years from grant, the original patent likely expired around 2000, although secondary patents could still provide some exclusivity.

3. How does this patent influence current drug development?
It provides a structural and synthetic blueprint for developing benzazepine-based neuroleptics, influencing both branded and generic drug markets.

4. What are the key features to look for in derivative patents building upon 4,357,324?
Substitutions on the core heterocycle, novel salts or prodrugs, formulation innovations, and suggested therapeutic indications are primary focus areas.

5. Which regulatory and patent policies govern such neuropharmaceutical patents?
FDA Regulations govern approval, while USPTO patent laws—particularly regarding novelty, non-obviousness, and utility—dictate patent scope and validity.

References

[1] U.S. Patent 4,357,324, Eli Lilly, issued Nov. 2, 1982.
[2] M. Seeman et al., “Dopamine D2 receptor antagonists,” Pharmacology Reviews, 2002.
[3] W. P. Van Engelen et al., “Benzazepines in neuropharmacology,” Journal of Medicinal Chemistry, 1995.
[4] U.S. Patent 4,552,852; 1985.
[5] Eli Lilly & Co., “Antipsychotic agents and methods,” US Patent Application, 1980.

Details for Patent: 4,357,324

Summary for Patent: 4,357,324